• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Tandem Diabetes Care Inc. (Amendment)

    5/10/23 1:46:04 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care
    Get the next $TNDM alert in real time by email
    SC 13G/A 1 SEC13G_Filing.htm SEC SCHEDULE 13G

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 3 )*

                

    Tandem Diabetes Care, Inc.


    (Name of Issuer)

    Common Stock


    (Title of Class of Securities)

    875372203


    (CUSIP Number)

    April 28, 2023


    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [X] Rule 13d-1(b)
    [ ] Rule 13d-1(c)
    [ ] Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes.)


    CUSIP No. 875372203

    1. NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

    Capital World Investors
    95-1411037
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a) [ ]
    (b) [ ]
    3. SEC USE ONLY
    4. CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

    5. SOLE VOTING POWER 6,448,368
    6. SHARED VOTING POWER 0
    7. SOLE DISPOSITIVE POWER 6,473,192
    8. SHARED DISPOSITIVE POWER 0
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    6,473,192 Beneficial ownership disclaimed pursuant to Rule 13d-4
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    [ ]
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    10.0%
    12. TYPE OF REPORTING PERSON

    IA

    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    


    Item 1.
    (a) Name of Issuer
    Tandem Diabetes Care, Inc.
    (b) Address of Issuer's Principal Executive Offices
    11075 Roselle Street, San Diego, CA 92121
    Item 2.
    (a) Name of Person Filing
    Capital World Investors
    (b) Address of Principal Business Office or, if None, Residence
    333 SOUTH HOPE STREET, 55TH FLOOR, LOS ANGELES, CALIFORNIA 90071
    (c) Citizenship
    N/A
    (d) Title of Class of Securities
    Common Stock
    (e) CUSIP Number
    875372203
    Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:
    (a) [ ] Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
    (b) [ ] Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c) [ ] Insurance Company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d) [ ] Investment Company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
    (e) [X] An investment adviser in accordance with Rule 240.13d-1(b)(1)(ii)(E);
    (f) [ ] An employee benefit plan or endowment fund in accordance with Rule 240.13d-1(b)(1)(ii)(F);
    (g) [ ] A parent holding company or control person in accordance with Rule 240.13d-1(b)(1)(ii)(G);
    (h) [ ] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i) [ ] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j) [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(J).
    Item 4. Ownership.
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
    (a) Amount Beneficially Owned:
    6,473,192 **
    (b) Percent of Class:
    10.0%
    (c) Number of shares as to which such person has:
    (i) sole power to vote or to direct the vote 6,448,368
    (ii) shared power to vote or to direct the vote 0
    (iii) sole power to dispose or to direct the disposition of 6,473,192
    (iv) shared power to dispose or to direct the disposition of 0
    **Capital World Investors ("CWI") is a division of Capital Research and Management Company ("CRMC"), as well as its investment management subsidiaries and affiliates Capital Bank and Trust Company, Capital International, Inc., Capital International Limited, Capital International Sarl, Capital International K.K., Capital Group Private Client Services, Inc., and Capital Group Investment Management Private Limited (together with CRMC, the "investment management entities"). CWI's divisions of each of the investment management entities collectively provide investment management services under the name "Capital World Investors." CWI is deemed to be the beneficial owner of 6,473,192 shares or 10.0% of the 64,606,732 shares believed to be outstanding.
    Item 5. Ownership of Five Percent or Less of Class.
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: [ ]
    Item 6. Ownership of More than Five Percent on Behalf of Another Person.
    SMALLCAP World Fund, Inc.
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
    Not Applicable
    Item 8. Identification and Classification of Members of the Group.

    Not Applicable. This schedule is not being filed pursuant to Rule 13d-1(b)(1)(ii)(J) or Rule 13d-1(d).
    Item 9. Notice of Dissolution of Group.

    Not Applicable
    Item 10. Certification.

    By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Capital World Investors
    By: /s/ Erik A. Vayntrub
    Date: May 10, 2023
    Name: Erik A. Vayntrub
    Title: Senior Vice President and Senior Counsel, Fund Business Management Group, Capital Research and Management Company

    Get the next $TNDM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TNDM

    DatePrice TargetRatingAnalyst
    4/10/2025$20.00Neutral
    Mizuho
    3/5/2025$45.00 → $22.00Overweight → Equal-Weight
    Morgan Stanley
    3/4/2025$35.00 → $24.00Buy → Neutral
    Citigroup
    3/3/2025$38.00 → $22.00Overweight → Equal Weight
    Wells Fargo
    2/28/2025$35.00 → $25.00Outperform → Mkt Perform
    Bernstein
    12/2/2024$45.00Equal-Weight → Overweight
    Morgan Stanley
    11/6/2024$42.00Outperform
    Bernstein
    10/4/2024$46.00Neutral
    Goldman
    More analyst ratings

    $TNDM
    Leadership Updates

    Live Leadership Updates

    See more
    • Tandem Diabetes Care Appoints Jean-Claude Kyrillos as Chief Operating Officer

      Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, today announced the appointment of Jean-Claude "JC" Kyrillos as Executive Vice President and Chief Operating Officer, effective June 21, 2024. Mr. Kyrillos comes to Tandem with more than 20 years of global executive leadership experience in medical device, digital health, and healthcare management. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240620151195/en/Jean-Claude "JC" Kyrillos (Photo: Business Wire) "JC brings deep experience in healthcare and a great balance of technical, operational, and leadership skills from multipl

      6/20/24 9:00:00 AM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Tandem Diabetes Care, Inc investors: Please contact the Portnoy Law Firm to recover your losses; November 2, 2023 deadline

      Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Nov. 07, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Tandem Diabetes Care, Inc. ("Tandem" or the "Company") (NASDAQ:TNDM) investors that a lawsuit filed on behalf of investors that purchased Tandem securities between August 3, 2022 and November 2, 2022, inclusive (the "Class Period") Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' optio

      11/7/23 3:47:00 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Tandem Diabetes Care, Inc investors: Please contact the Portnoy Law Firm to recover your losses; November 2, 2023 deadline.

      Investors can contact the law firm at no cost to learn more about recovering their losses ​LOS ANGELES, Nov. 01, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Tandem Diabetes Care, Inc. ("Tandem" or the "Company") (NASDAQ:TNDM) investors that a lawsuit filed on behalf of investors that purchased Tandem securities between August 3, 2022 and November 2, 2022, inclusive (the "Class Period") Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' opti

      11/1/23 8:03:30 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care

    $TNDM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Tandem Diabetes Care Announces Upcoming Conference Presentations

      Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, today announced that management will present a company update at the following investor conferences: 2025 RBC Capital Markets Global Healthcare Conference on Tuesday, May 20, 2025 at 10:00am Eastern Time (7:00am Pacific Time), Jefferies Global Healthcare Conference on Wednesday, June 4, 2025 at 3:45pm Eastern Time (12:45pm Pacific Time), and Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2025 at 8:40am Eastern Time (5:40am Pacific Time). The presentations will be webcast live, and an archive recording will be available for 30 days. The link to the live w

      5/6/25 4:05:00 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Tandem Diabetes Care Announces First Quarter 2025 Financial Results

      Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended March 31, 2025. First Quarter 2025 Highlights, Financial Results Compared to First Quarter 2024 Achieved record first quarter sales with worldwide growth of 22% Increased pump sales in the United States by 19% on a GAAP basis and 17% on a non-GAAP(1) basis, on strong shipment growth and average selling price improvement Delivered 5 point adjusted EBITDA(1) margin increase Approximately 30% of U.S. lives now covered through pharmacy benefits for Tandem Mobi Benefits of Control-IQ Technology were featured for a fourth time i

      4/30/25 4:05:00 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Tandem Diabetes Care to Announce First Quarter 2025 Financial Results on April 30, 2025

      Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, plans to release its first quarter 2025 results after the financial markets close on Wednesday, April 30, 2025. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its first quarter 2025 financial and operating results. A live webcast of the call will be available on Tandem Diabetes Care's Investor Center website located at http://investor.tandemdiabetes.com in the "Events & Presentations" section. To access the call by phone, please use this link (https://register-conf.media-server.com/register/BI72222

      4/3/25 4:05:00 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care

    $TNDM
    SEC Filings

    See more
    • SEC Form 10-Q filed by Tandem Diabetes Care Inc.

      10-Q - TANDEM DIABETES CARE INC (0001438133) (Filer)

      4/30/25 4:11:29 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Tandem Diabetes Care Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - TANDEM DIABETES CARE INC (0001438133) (Filer)

      4/30/25 4:06:30 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • SEC Form DEF 14A filed by Tandem Diabetes Care Inc.

      DEF 14A - TANDEM DIABETES CARE INC (0001438133) (Filer)

      4/8/25 5:10:34 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care

    $TNDM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP & Chief Operating Officer Kyrillos Jean-Claude bought $190,966 worth of shares (10,538 units at $18.12) (SEC Form 4)

      4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)

      3/11/25 6:06:01 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • EVP & CHIEF COMMERCIAL OFFICER Novara Mark David bought $12,364 worth of shares (532 units at $23.24) (SEC Form 4)

      4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)

      11/19/24 5:23:14 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Allen Dick bought $94,778 worth of shares (5,000 units at $18.96), increasing direct ownership by 33% to 19,962 units (SEC Form 4)

      4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)

      11/29/23 4:10:39 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care

    $TNDM
    Financials

    Live finance-specific insights

    See more
    • Tandem Diabetes Care Announces First Quarter 2025 Financial Results

      Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended March 31, 2025. First Quarter 2025 Highlights, Financial Results Compared to First Quarter 2024 Achieved record first quarter sales with worldwide growth of 22% Increased pump sales in the United States by 19% on a GAAP basis and 17% on a non-GAAP(1) basis, on strong shipment growth and average selling price improvement Delivered 5 point adjusted EBITDA(1) margin increase Approximately 30% of U.S. lives now covered through pharmacy benefits for Tandem Mobi Benefits of Control-IQ Technology were featured for a fourth time i

      4/30/25 4:05:00 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Tandem Diabetes Care to Announce First Quarter 2025 Financial Results on April 30, 2025

      Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, plans to release its first quarter 2025 results after the financial markets close on Wednesday, April 30, 2025. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its first quarter 2025 financial and operating results. A live webcast of the call will be available on Tandem Diabetes Care's Investor Center website located at http://investor.tandemdiabetes.com in the "Events & Presentations" section. To access the call by phone, please use this link (https://register-conf.media-server.com/register/BI72222

      4/3/25 4:05:00 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Tandem Diabetes Care Announces Fourth Quarter and Full Year 2024 Financial Results and 2025 Financial Guidance

      Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter and fiscal year ended December 31, 2024 and provided its financial guidance for the year ending December 31, 2025. Fourth Quarter 2024 Financial Highlights compared to Fourth Quarter 2023 Achieved record sales as worldwide GAAP sales grew 44 percent to $282.6 million and worldwide non-GAAP sales(1) grew 21 percent to $252.4 million. Increased worldwide pump shipments by more than 25 percent. Grew the United States insulin pump market by achieving a double-digit increase in people converting from multiple daily injections. Ful

      2/26/25 4:05:00 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care

    $TNDM
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • February 28, 2025 - FDA Roundup: February 28, 2025

      For Immediate Release: February 28, 2025 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:On Thursday, the FDA approved Odactra to include use in individuals 5 through 11 years of age to treat house dust mite induced nasal inflammation (allergic rhinitis), with or without eye inflammation (conjunctivitis). Odactra is an allergen extract immunotherapy

      2/28/25 5:00:47 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • November 7, 2023 - FDA Roundup: November 7, 2023

      For Immediate Release: November 07, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  On Monday, the FDA issued a Safety Communication warning consumers, health care providers, and health care facilities not to use recalled saline (0.9% sodium chloride) and sterile water medical products manufactured by Nurse Assist, LLC. On November 6, Nurse

      11/7/23 3:38:18 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care

    $TNDM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Tandem Diabetes Care Inc.

      SC 13G/A - TANDEM DIABETES CARE INC (0001438133) (Subject)

      11/14/24 4:15:44 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Tandem Diabetes Care Inc.

      SC 13G/A - TANDEM DIABETES CARE INC (0001438133) (Subject)

      9/9/24 10:40:31 AM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Tandem Diabetes Care Inc.

      SC 13G - TANDEM DIABETES CARE INC (0001438133) (Subject)

      2/14/24 7:37:31 AM ET
      $TNDM
      Medical/Dental Instruments
      Health Care

    $TNDM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP & CHIEF COMMERCIAL OFFICER Novara Mark David converted options into 7,415 shares and covered exercise/tax liability with 2,739 shares, increasing direct ownership by 24% to 24,134 units (SEC Form 4)

      4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)

      3/19/25 4:12:32 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Chief Technology Officer Carpenter Rick converted options into 406 shares and covered exercise/tax liability with 146 shares, increasing direct ownership by 2% to 16,392 units (SEC Form 4)

      4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)

      3/19/25 4:12:22 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • EVP & Chief Operating Officer Kyrillos Jean-Claude bought $190,966 worth of shares (10,538 units at $18.12) (SEC Form 4)

      4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)

      3/11/25 6:06:01 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care

    $TNDM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Mizuho initiated coverage on Tandem Diabetes Care with a new price target

      Mizuho initiated coverage of Tandem Diabetes Care with a rating of Neutral and set a new price target of $20.00

      4/10/25 12:43:51 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Tandem Diabetes Care downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Tandem Diabetes Care from Overweight to Equal-Weight and set a new price target of $22.00 from $45.00 previously

      3/5/25 7:47:44 AM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Tandem Diabetes Care downgraded by Citigroup with a new price target

      Citigroup downgraded Tandem Diabetes Care from Buy to Neutral and set a new price target of $24.00 from $35.00 previously

      3/4/25 7:45:44 AM ET
      $TNDM
      Medical/Dental Instruments
      Health Care